The humanized anti-HER2 monoclonal antibody, trastuzumab (Herceptin), was the first oncogene-targeted therapy [4], and its use over the last 25 years has improved disease-free and overall survival in patients with early and advanced-stage HER2 + breast cancer [5–8]. The gene discussed is ERBB2; the disease is breast cancer.